Caseware UK (AP4) 2024.0.164 2024.0.164 2025-12-312025-12-310true2025-01-0143falseThe principal activity of Xampla Ltd (the ‘Company’) is to develop and commercialise high-performance resins andmaterials from non-chemically modified natural biopolymers to create scalable, reliable, drop-in replacements for plasticfilms, microcapsules and coatings.41falsefalse 11637116 2025-01-01 2025-12-31 11637116 2024-01-01 2024-12-31 11637116 2025-12-31 11637116 2024-12-31 11637116 1 2025-01-01 2025-12-31 11637116 d:Director4 2025-01-01 2025-12-31 11637116 c:PlantMachinery 2025-01-01 2025-12-31 11637116 c:PlantMachinery 2025-12-31 11637116 c:PlantMachinery 2024-12-31 11637116 c:PlantMachinery c:OwnedOrFreeholdAssets 2025-01-01 2025-12-31 11637116 c:FurnitureFittings 2025-01-01 2025-12-31 11637116 c:FurnitureFittings 2025-12-31 11637116 c:FurnitureFittings 2024-12-31 11637116 c:FurnitureFittings c:OwnedOrFreeholdAssets 2025-01-01 2025-12-31 11637116 c:ComputerEquipment 2025-01-01 2025-12-31 11637116 c:ComputerEquipment 2025-12-31 11637116 c:ComputerEquipment 2024-12-31 11637116 c:ComputerEquipment c:OwnedOrFreeholdAssets 2025-01-01 2025-12-31 11637116 c:OwnedOrFreeholdAssets 2025-01-01 2025-12-31 11637116 c:PatentsTrademarksLicencesConcessionsSimilar 2025-01-01 2025-12-31 11637116 c:PatentsTrademarksLicencesConcessionsSimilar 2025-12-31 11637116 c:PatentsTrademarksLicencesConcessionsSimilar 2024-12-31 11637116 c:ComputerSoftware 2025-12-31 11637116 c:ComputerSoftware 2024-12-31 11637116 c:CurrentFinancialInstruments 2025-12-31 11637116 c:CurrentFinancialInstruments 2024-12-31 11637116 c:Non-currentFinancialInstruments 2025-12-31 11637116 c:Non-currentFinancialInstruments 2024-12-31 11637116 c:CurrentFinancialInstruments c:WithinOneYear 2025-12-31 11637116 c:CurrentFinancialInstruments c:WithinOneYear 2024-12-31 11637116 c:ShareCapital 2025-12-31 11637116 c:ShareCapital 2024-12-31 11637116 c:SharePremium 2025-01-01 2025-12-31 11637116 c:SharePremium 2025-12-31 11637116 c:SharePremium 2024-12-31 11637116 c:OtherMiscellaneousReserve 2025-01-01 2025-12-31 11637116 c:OtherMiscellaneousReserve 2025-12-31 11637116 c:OtherMiscellaneousReserve 2024-12-31 11637116 c:RetainedEarningsAccumulatedLosses 2025-01-01 2025-12-31 11637116 c:RetainedEarningsAccumulatedLosses 2025-12-31 11637116 c:RetainedEarningsAccumulatedLosses 2024-12-31 11637116 c:FurtherSpecificTypeProvisionContingentLiability1ComponentTotalProvisionsContingentLiabilities 2025-12-31 11637116 c:FurtherSpecificTypeProvisionContingentLiability1ComponentTotalProvisionsContingentLiabilities 2024-12-31 11637116 d:FRS102 2025-01-01 2025-12-31 11637116 d:Audited 2025-01-01 2025-12-31 11637116 d:FullAccounts 2025-01-01 2025-12-31 11637116 d:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 11637116 c:WithinOneYear 2025-12-31 11637116 c:WithinOneYear 2024-12-31 11637116 c:BetweenOneFiveYears 2025-12-31 11637116 c:BetweenOneFiveYears 2024-12-31 11637116 d:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 11637116 c:PatentsTrademarksLicencesConcessionsSimilar c:ExternallyAcquiredIntangibleAssets 2025-01-01 2025-12-31 11637116 c:ComputerSoftware c:ExternallyAcquiredIntangibleAssets 2025-01-01 2025-12-31 11637116 c:ExternallyAcquiredIntangibleAssets 2025-01-01 2025-12-31 11637116 c:PatentsTrademarksLicencesConcessionsSimilar c:OwnedIntangibleAssets 2025-01-01 2025-12-31 11637116 c:ComputerSoftware c:OwnedIntangibleAssets 2025-01-01 2025-12-31 11637116 e:PoundSterling 2025-01-01 2025-12-31 iso4217:GBP xbrli:pure

Registered number: 11637116










XAMPLA LTD










FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 DECEMBER 2025


 
XAMPLA LTD
REGISTERED NUMBER: 11637116

BALANCE SHEET
AS AT 31 DECEMBER 2025

2025
2024
Note
£
£

Fixed assets
  

Intangible fixed assets
 4 
1,128
-

Tangible fixed assets
 5 
238,881
474,087

  
240,009
474,087

Current assets
  

Debtors: amounts falling due after more than one year
 6 
38,056
38,056

Debtors: amounts falling due within one year
 6 
971,865
1,110,780

Bank and cash balances
  
7,174,363
835,754

  
8,184,284
1,984,590

Creditors: amounts falling due within one year
 7 
(355,898)
(426,065)

Net current assets
  
 
 
7,828,386
 
 
1,558,525

Total assets less current liabilities
  
8,068,395
2,032,612

Provisions
 8 
(31,000)
(31,000)

Net assets
  
8,037,395
2,001,612


Capital and reserves
  

Called up share capital 
  
1,271
340

Share premium account
 12 
25,418,431
15,157,576

Other reserves
 12 
2,051,684
1,711,445

Profit and loss account
 12 
(19,433,991)
(14,867,749)

  
8,037,395
2,001,612


The Company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 1 July 2026.


A C French
Director

The notes on pages 2 to 14 form part of these financial statements.

Page 1

 
XAMPLA LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

1.


GENERAL INFORMATION

Xampla Ltd (Company number - 11637116) is a private company limited by shares incorporated in England. The Company's registered office and principal place of business is Bio-Innovation Centre, 25 Cambridge Science Park Road, Cambridge, CB4 0FW.

2.ACCOUNTING POLICIES

 
2.1

BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies.

The following principal accounting policies have been applied:

 
2.2

GOING CONCERN

The Company incurred a net loss of £4,566,242 during the year ended 31 December 2025 and as at the balance sheet date the company had net assets amounting to £8,037,395 and cash at bank amounting to £7,174,363.

The Company intends to continue to invest in research and development activities as well as developing commercial relationships with customers, to increase revenue and to ensure that it remains in a position to fully exploit the growing opportunities in the areas of drop-in replacements for plastic films, microcapsules and coatings.

The Company is dependent on external funding while it continues to develop and commercialise its technology through research and development activities, in order that in the future it can license or sell the developed technology to generate cash inflows. The Company is expected to be loss making and in a net cash outflow position until at least 2027 as it progresses these activities and may need to generate further funding from either current or new investors or through debt financing.

The financial statements have been prepared on the going concern basis, which assumes that the
Company will continue in operational existence and will be able to meet liabilities as they fall due. In
July 2025 the Company closed a £10m Series-A financing round. In March 2026 the Company extended the Series-A financing round to allow an additional £3m equity investment to be received from two new investors.

This financing will enable the Company to continue to meet its liabilities for at least 12 months from the date of approval of the financial statements and into FY2028 without the need for additional investment. Based on the cash flow forecasts and support provided, the Directors have therefore prepared the accounts on a going concern basis.
 

Page 2

 
XAMPLA LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.ACCOUNTING POLICIES (CONTINUED)

 
2.3

REVENUE

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods
Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer, usually on dispatch of the goods, the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably. Written purchase authorisation's are obtained from customers for a specified amount of product at a specified price and delivery is considered to have occurred at the time of shipment, dependent on agreed shipping terms. If goods are maintained at a consigned location, revenue is recognised when customers take the product for its use.

Rendering of services
Revenue for professional services is invoiced in line with customer contracts and recognised on the basis of work performed. Where contracts indicate time and materials, as the basis for charges, revenue is recognised directly in line with work completed. Where this is not the case project plans detailing resource requirement during a project are used to establish percentage completion at any point in time. 

Licences
Revenue for licence fees is recognised when persuasive evidence for the arrangement exists, delivery has occurred, fees are fixed or determinable, non-refundable and require no further commitments with fee collection being probable.

 
2.4

GOVERNMENT GRANTS

Grants are recognised when it is reasonable to expect that the grants will be received and that all related conditions will be met, usually on submission of a valid claim for payment.

Government grants in respect of capital expenditure are credited to a deferred income account and are released to profit over the expected useful lives of the relevant assets by equal annual installments.

Grants of a revenue nature are recognised in profit or loss over the period in which the related costs are incurred.

Page 3

 
XAMPLA LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.ACCOUNTING POLICIES (CONTINUED)

 
2.5

INTANGIBLE ASSETS

Intangible assets acquired separately from a business are capitalised at cost. Intangible assets acquired as part of an acquisition of a business are capitalised separately from goodwill if the fair value can be measured reliably on initial recognition. Intangible assets, excluding development costs, created within the business are not capitalised and expenditure is charged against profits in the year in which it is incurred.

Subsequent to initial recognition, intangible assets are stated at cost less accumulated amortisation and accumulated impairment. Intangible assets are amortised on a straight line basis over their estimated useful lives. The carrying value of intangible assets is reviewed for impairment if events or changes in circumstances indicate the carrying value may not be recoverable.

 The estimated useful lives range as follows:

Software Licences
-
2 to 5 years

If there are indicators that the residual value or useful life of an intangible asset has changed since the most recent annual reporting period previous estimates shall be reviewed and, if current expectations differ, the residual value, amortisation method or useful life shall be amended. Changes in the expected useful life or the expected pattern of consumption of benefit shall be accounted for as a change in accounting estimate.

 
2.6

TANGIBLE FIXED ASSETS

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Plant and machinery
-
2 to 5 years
Fixtures and fittings
-
2 to 5 years
Computer equipment
-
2 to 5 years

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.7

OPERATING LEASES: THE COMPANY AS LESSEE

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

Benefits received and receivable as an incentive to sign an operating lease are recognised on a straight-line basis over the lease term, unless another systematic basis is representative of the time pattern of the lessee's benefit from the use of the leased asset.

Page 4

 
XAMPLA LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.ACCOUNTING POLICIES (CONTINUED)

 
2.8

RESEARCH AND DEVELOPMENT

Expenditure on research activities is recognised as an expense in the period in which it is incurred.

Development expenditure is recognised as an expense in the period in which it is incurred. This is a policy choice made by the directors, applied consistently in accordance with the reporting standard.

Research and development costs include direct staff costs, materials, and overheads attributable to the projects.

 
2.9

PROVISIONS FOR LIABILITIES

Provisions are recognised when an event has taken place that gives rise to a legal or constructive obligation, a transfer of economic benefits is probable and a reliable estimate can be made.

Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties.
 
Increases in provisions are generally charged as an expense to profit or loss.

 
2.10

TAXATION

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


Page 5

 
XAMPLA LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.ACCOUNTING POLICIES (CONTINUED)

 
2.11

FOREIGN CURRENCY TRANSLATION

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

 
2.12

CASH AND CASH EQUIVALENTS

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.13

PENSIONS

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds.

Page 6

 
XAMPLA LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.ACCOUNTING POLICIES (CONTINUED)

 
2.14

SHARE-BASED PAYMENTS

Where share options are awarded to employees, the fair value of the options at the date of grant is charged to profit or loss over the vesting period. Non-market vesting conditions are taken into account by adjusting the number of equity instruments expected to vest at each balance sheet date so that, ultimately, the cumulative amount recognised over the vesting period is based on the number of options that eventually vest. Market vesting conditions are factored into the fair value of the options granted. The cumulative expense is not adjusted for failure to achieve a market vesting condition.

The fair value of the award also takes into account non-vesting conditions. These are either factors beyond the control of either party (such as a target based on an index) or factors which are within the control of one or other of the parties (such as the Company keeping the scheme open or the employee maintaining any contributions required by the scheme).

Where the terms and conditions of options are modified before they vest, the increase in the fair value of the options, measured immediately before and after the modification, is also charged to profit or loss over the remaining vesting period.

Where equity instruments are granted to persons other than employees, profit or loss is charged with fair value of goods and services received.

Cash-settled share options are measured at fair value, with a liability recognised over the vesting period based on the number of awards expected to vest. The liability is remeasured at each reporting date until settlement, with changes recognised in profit or loss.

 
2.15

FINANCE COSTS

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.16

FINANCIAL INSTRUMENTS

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.

Debt instruments (other than those wholly repayable or receivable within one year), including loans and other accounts receivable and payable, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade debtors and creditors, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be paid or received. However, if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or in case of an out-right short-term loan that is not at market rate, the financial asset or liability is measured, initially at the present value of future cash flows discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost, unless it qualifies as a loan from a director in the case of a small company, or a public benefit entity concessionary loan.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Statement of comprehensive income.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If a financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the
Page 7

 
XAMPLA LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.ACCOUNTING POLICIES (CONTINUED)


2.16
FINANCIAL INSTRUMENTS (continued)

contract.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and best estimate of the recoverable amount, which is an approximation of the amount that the Company would receive for the asset if it were to be sold at the balance sheet date.

Financial assets and liabilities are offset and the net amount reported in the Balance sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

 
2.17

DEBTORS

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.18

CREDITORS

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.


3.


EMPLOYEES

Staff costs, including directors' remuneration, were as follows:


2025
2024
£
£

Wages and salaries
2,776,257
2,663,117

Social security costs
310,101
265,698

Pension costs
139,272
120,510

3,225,630
3,049,325


The average monthly number of employees, including the directors, during the year was as follows:


        2025
        2024
            No.
            No.







Research and development
26
28



Administration
8
8



Sales and marketing
7
7

41
43

Page 8

 
XAMPLA LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

4.


INTANGIBLE ASSETS




Intellectual property
Software
Total

£
£
£



Cost


At 1 January 2025
77,454
948
78,402


Additions
-
1,334
1,334



At 31 December 2025

77,454
2,282
79,736



Amortisation


At 1 January 2025
77,454
948
78,402


Charge for the year
-
206
206



At 31 December 2025

77,454
1,154
78,608



Net book value



At 31 December 2025
-
1,128
1,128



At 31 December 2024
-
-
-


Page 9

 
XAMPLA LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

5.


TANGIBLE FIXED ASSETS


Plant and equipment
Fixtures and fittings
Computer equipment
Total

£
£
£
£



Cost or valuation


At 1 January 2025
846,550
345,506
51,905
1,243,961


Additions
18,652
6,781
-
25,433



At 31 December 2025

865,202
352,287
51,905
1,269,394



Depreciation


At 1 January 2025
610,339
121,942
37,593
769,874


Charge for the year
139,165
114,432
7,042
260,639



At 31 December 2025

749,504
236,374
44,635
1,030,513



Net book value



At 31 December 2025
115,698
115,913
7,270
238,881



At 31 December 2024
236,211
223,564
14,312
474,087

Page 10

 
XAMPLA LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

6.


DEBTORS

2025
2024
£
£

Due after more than one year

Other debtors
38,056
38,056

38,056
38,056


2025
2024
£
£

Due within one year

Trade debtors
58,105
21,805

Other debtors
70,179
64,013

Prepayments and accrued income
351,431
395,104

Tax recoverable
492,150
629,858

971,865
1,110,780



7.


CREDITORS: Amounts falling due within one year

2025
2024
£
£

Trade creditors
72,891
122,696

Other taxation and social security
92,456
81,608

Other creditors
53,737
67,504

Accruals and deferred income
136,814
154,257

355,898
426,065



8.


PROVISIONS





Dilapidations provision

£





At 1 January 2025
31,000



At 31 December 2025
31,000

Page 11

 
XAMPLA LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

9.


Allotted, called up and fully paid share capital

2025
No.
2025
£
2024
No.
2024
£
Ordinary shares of £0.0001 each

3,344,430

335

1,197,435
 
120
 
Deferred shares of £0.0001 each

33,408

3

33,408
 
3
 
Seed shares of £0.0001 each

773,432

77

773,432
 
77
 
Seed 2 shares of £0.0001 each

644,445

64

644,445
 
64
 
Seed 3 shares of £0.0001 each

584,692

58

584,692
 
58
 
Seed 4 shares of £0.0001 each

36,543

4

164,438
 
16
 
Series A1 shares of £0.0001 each

5,508,967

551

-
 
-
 
Series A2 shares of £0.0001 each

1,786,165

179

-
 
-
 
12,712,082

1,271

3,397,850
 
338
 

The Ordinary Shares have full rights regarding voting, payment of dividends and distributions.

The Seed Shares have the right to vote, receive dividends and participate in a distribution (including on a winding up). The Seed shares are not redeemable.

The Series A1 Shares have the right to vote, receive dividends and participate in a distribution (including on a winding up). The Series A1 shares are redeemable under certain conditions, subject to Board consent.
 
The Series A2 Shares have the right to vote, receive dividends and participate in a distribution (including on a winding up). The Series A2 shares are not redeemable.


10.

Authorised share capital

2025
No.
2025
£
2024
No.
2024
£
Ordinary shares of £0.0001 each

5,337,392

530

1,849,402
 
185
 
Deferred shares of £0.0001 each

33,408

3

33,408
 
3
 
Seed shares of £0.0001 each

773,432

77

773,432
 
77
 
Seed 2 shares of £0.0001 each

644,445

64

644,445
 
64
 
Seed 3 shares of £0.0001 each

584,692

58

584,692
 
58
 
Seed 4 shares of £0.0001 each

36,543

4

164,438
 
16
 
Series A1 shares of £0.0001 each

5,508,967

551

-
 
-
 
Series A2 shares of £0.0001 each

1,786,165

179

-
 
-
 

14,705,044

1,466

4,049,817
 
403
 

Page 12

 
XAMPLA LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

11.


Share-based payments

The following table summarises the number and weighted average exercise prices (‘WAEP’) of, and movements in, share options during the year ended 31 December 2025.

ole32e1.png

The fair value of each equity-settled share option is estimated as at the date of grant using the Black-Scholes model, taking into account the terms and conditions upon which the options were granted. The weighted average fair value of options granted during the year was £1.000. The options will vest over a four year period from grant date which in turn is based on employee start date.


12.


RESERVES

Share premium account

This reserve records the amount above the nominal value received for shares issued, less transaction costs.

Other reserves

This reserve represents capital contributions made by the company in respect of share based compensation.

Profit and loss account

This reserve includes all current and previous retained losses of the Company net of any distributions.


13.


PENSION COMMITMENTS

The Company operates a defined contribution pension scheme with employees also contributing to the scheme. The pension cost charge amounted to £139,272 (2024 - £120,510). The creditor outstanding at 31 December 2025 was £39,503 (2024 - £43,729).

Page 13

 
XAMPLA LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

14.


COMMITMENTS UNDER OPERATING LEASES

At 31 December 2025 the Company had future minimum lease payments due under non-cancellable operating leases for each of the following periods:

2025
2024
£
£


Not later than 1 year
402,076
404,663

Later than 1 year and not later than 5 years
958,456
1,366,943

1,360,532
1,771,606


15.


RELATED PARTY TRANSACTIONS

Total amounts paid to key management personnel in the year amounted to £707,372 (2024 - £642,210). Key management personnel are those who are involved in the strategic decisions of the Company.


16.


POST BALANCE SHEET EVENTS

In January 2026, £2,968 was received from existing investors relating to the issue of 292,086 Series A1
shares and 4,665 Series A2 shares.
 
In March 2026, £1,500,466 was received from a new investor relating to the issue of 964,819 Series A2 shares. Additionally, £16 was received from an existing investor relating to the issue of 155,898 Ordinary shares.
 
In April 2026, £1,500,000 was received from a new investor relating to the issue of 918,161 Series A1 shares.  Additionally, £653 was received from an existing investor relating to the issue of 65,319 Series A1 shares.

In May 2026, £1,097 was received from former employees relating to the issue of vested options over 13,311 Ordinary shares.


17.


AUDITORS' INFORMATION

The auditors' report on the financial statements for the year ended 31 December 2025 was unqualified.

The audit report was signed on 2 July 2026 by Adam Norman (Senior Statutory Auditor) on behalf of Price Bailey LLP.


Page 14